A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors
详细信息 查看全文
- 作者：Christian Dittrich (1)
Michael A. Fridrik (2)
Robert Koenigsberg (1)
Chooi Lee (3)
Rainer-Georg Goeldner (4)
James Hilbert (5)
Richard Greil (6)
1. Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) 鈥?LB Cluster Translational Oncology and Applied Cancer Research-Institution for Translational Research Vienna (ACR-ITR VIEnna) ; Third Medical Department ; Center for Oncology and Hematology ; Kaiser-Franz-Josef-Spital ; Vienna ; Austria
2. Center for Hematology and Medical Oncology ; General Hospital Linz ; Linz ; Austria
3. Boehringer Ingelheim Ltd. ; Bracknell ; Berkshire ; UK
4. Boehringer Ingelheim Pharma GmbH & Co. KG ; Biberach an der Ri脽 ; Germany
5. Boehringer Ingelheim Pharmaceuticals ; Inc ; Ridgefield ; CT ; USA
6. Third Medical Department of Hematology ; Medical Oncology ; Hemostaseology ; Rheumatology and Infectiology ; Salzburg Cancer Research Institute ; Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR) and Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT) ; Paracelsus Medical University ; Salzburg ; Austria - 关键词：Aurora kinase ; Clinical trials ; Phase 1 ; Maximum tolerated dose ; Pharmacodynamics ; Pharmacokinetics ; Solid tumors
- 刊名：Investigational New Drugs
- 出版年：2015
- 出版时间：April 2015
- 年：2015
- 卷：33
- 期：2
- 页码：409-422
- 全文大小：2,495 KB
- 参考文献：1. Green, MR, Woolery, JE, Mahadevan, D (2011) Update on aurora kinase targeted therapeutics in oncology. Expert Opin Drug Discov 6: pp. 291-307 CrossRef
2. Kollareddy, M, Zheleva, D, Dzubak, P, Brahmkshatriya, PS, Lepsik, M, Hajduch, M (2012) Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs 30: pp. 2411-2432 CrossRef
3. Marumoto, T, Honda, S, Hara, T, Nitta, M, Hirota, T, Kohmura, E, Saya, H (2003) Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 278: pp. 51786-51795 CrossRef
4. Carmena, M, Earnshaw, WC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4: pp. 842-854 CrossRef
5. Adams, RR, Maiato, H, Earnshaw, WC, Carmena, M (2001) Essential roles of Drosophila inner centromere protein (INCENP) and aurora B in histone H3 phosphorylation, metaphase chromosome alignment, kinetochore disjunction, and chromosome segregation. J Cell Biol 153: pp. 865-880 CrossRef
6. Goto, H, Yasui, Y, Nigg, EA, Inagaki, M (2002) Aurora-B phosphorylates Histone H3 at serine28 with regard to the mitotic chromosome condensation. Genes Cells 7: pp. 11-17 CrossRef
7. Hans, F, Dimitrov, S (2001) Histone H3 phosphorylation and cell division. Oncogene 20: pp. 3021-3027 CrossRef
8. Ota, T, Suto, S, Katayama, H, Han, ZB, Suzuki, F, Maeda, M, Tanino, M, Terada, Y, Tatsuka, M (2002) Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 62: pp. 5168-5177
9. Katayama, H, Ota, T, Jisaki, F, Ueda, Y, Tanaka, T, Odashima, S, Suzuki, F, Terada, Y, Tatsuka, M (1999) Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 91: pp. 1160-1162 CrossRef
10. Sorrentino, R, Libertini, S, Pallante, PL, Troncone, G, Palombini, L, Bavetsias, V, Spalletti-Cernia, D, Laccetti, P, Linardopoulos, S, Chieffi, P, Fusco, A, Portella, G (2005) Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 90: pp. 928-935 CrossRef
11. Zeng, WF, Navaratne, K, Prayson, RA, Weil, RJ (2007) Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. J Clin Pathol 60: pp. 218-221 CrossRef
12. Scheulen ME, Mross K, Richly H, Nokay B, Frost A, Scharr D (2010) A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered on Day 1 and 15 every 4聽weeks, in patients with advanced solid tumours. Eur J Cancer(Supplement 8):496, abstr
13. Therasse, P, Arbuck, SG, Eisenhauer, EA, Wanders, J, Kaplan, RS, Rubinstein, L, Verweij, J, Glabbeke, M, Oosterom, AT, Christian, MC, Gwyther, SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: pp. 205-216 CrossRef
14. Carpinelli, P, Moll, J (2008) Aurora kinase inhibitors: identification and preclinical validation of their biomarkers. Expert Opin Ther Targets 12: pp. 69-80 CrossRef
15. Graeser, R, Birkle, M, Rentzsch, C, Schaechtele, C (2010) A combined IHC/Western method to measure phosphorylated histone H3 in skin biopsies as potential biomarker for anticancer drug action. Cancer Res 70: pp. 4665 CrossRef
16. Gambacorti-Passerini, C, Zucchetti, M, Russo, D, Frapolli, R, Verga, M, Bungaro, S, Tornaghi, L, Rossi, F, Pioltelli, P, Pogliani, E, Alberti, D, Corneo, G, D'Incalci, M (2003) Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 9: pp. 625-632
17. Gibbons, J, Egorin, MJ, Ramanathan, RK, Fu, P, Mulkerin, DL, Shibata, S, Takimoto, CH, Mani, S, LoRusso, PA, Grem, JL, Pavlick, A, Lenz, HJ, Flick, SM, Reynolds, S, Lagattuta, TF, Parise, RA, Wang, Y, Murgo, AJ, Ivy, SP, Remick, SC (2008) Phase I and pharmacokinetic study of Imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute organ dysfunction working group. J Clin Oncol 26: pp. 570-576 CrossRef
18. Mross K, Scheulen M, Frost A, Scharr D, Richly H, Nokay B, Lee K, Hilbert J, Fleischer F, Fietz O (2010) A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors. J Clin Oncol 28:3011, abstr
19. Aftimos P, Dumez H, Awada A, Billiet M, Deleporte A, De Block K, Costermans J, Meeus M-A, Goeldner R-G, Schnell D, Lee C, Sch枚ffski P (2013) Phase I study of two dosing schedules of BI 847325, an orally administered dual inhibitor of MEK and aurora kinase B, in patients with advanced solid tumors. Mol Cancer Ther (Supplement 12):B281, abstr
20. Dewerth, A, Wonner, T, Lieber, J, Ellerkamp, V, Warmann, SW, Fuchs, J, Armeanu-Ebinger, S (2012) In vitro evaluation of the Aurora kinase inhibitor VX-680 for hepatoblastoma. Pediatr Surg Int 28: pp. 579-589 CrossRef
21. Xie, H, Lee, MH, Zhu, F, Reddy, K, Peng, C, Li, Y, Lim, DY, Kim, DJ, Li, X, Kang, S, Li, H, Ma, W, Lubet, RA, Ding, J, Bode, AM, Dong, Z (2013) Identification of an Aurora kinase inhibitor specific for the Aurora B isoform. Cancer Res 73: pp. 716-724 CrossRef
22. Fraedrich, K, Schrader, J, Ittrich, H, Keller, G, Gontarewicz, A, Matzat, V, Kromminga, A, Pace, A, Moll, J, Blaker, M, Lohse, AW, Horsch, D, Brummendorf, TH, Benten, D (2012) Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model. Clin Cancer Res 18: pp. 4621-4632 CrossRef
23. Aihara, A, Tanaka, S, Yasen, M, Matsumura, S, Mitsunori, Y, Murakata, A, Noguchi, N, Kudo, A, Nakamura, N, Ito, K, Arii, S (2010) The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol 52: pp. 63-71 CrossRef
24. Wilkinson, RW, Odedra, R, Heaton, SP, Wedge, SR, Keen, NJ, Crafter, C, Foster, JR, Brady, MC, Bigley, A, Brown, E, Byth, KF, Barrass, NC, Mundt, KE, Foote, KM, Heron, NM, Jung, FH, Mortlock, AA, Boyle, FT, Green, S (2007) AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13: pp. 3682-3688 CrossRef
25. Linder, S, Havelka, AM, Ueno, T, Shoshan, MC (2004) Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett 214: pp. 1-9 CrossRef
26. Olofsson, MH, Ueno, T, Pan, Y, Xu, R, Cai, F, Kuip, H, Muerdter, TE, Sonnenberg, M, Aulitzky, WE, Schwarz, S, Andersson, E, Shoshan, MC, Havelka, AM, Toi, M, Linder, S (2007) Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 13: pp. 3198-3206 CrossRef
27. Jackson, JR, Patrick, DR, Dar, MM, Huang, PS (2007) Targeted anti-mitotic therapies: can we improve on tubulin agents?. Nat Rev Cancer 7: pp. 107-117 CrossRef
28. Dees, EC, Cohen, RB, Mehren, M, Stinchcombe, TE, Liu, H, Venkatakrishnan, K, Manfredi, M, Fingert, H, Burris, HA, Infante, JR (2012) Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 18: pp. 4775-4784 CrossRef
29. Cervantes, A, Elez, E, Roda, D, Ecsedy, J, Macarulla, T, Venkatakrishnan, K, Rosello, S, Andreu, J, Jung, J, Sanchis-Garcia, JM, Piera, A, Blasco, I, Manos, L, Perez-Fidalgo, JA, Fingert, H, Baselga, J, Tabernero, J (2012) Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora A kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18: pp. 4764-4774 CrossRef
30. Cohen, RB, Jones, SF, Aggarwal, C, Mehren, M, Cheng, J, Spigel, DR, Greco, FA, Mariani, M, Rocchetti, M, Ceruti, R, Comis, S, Laffranchi, B, Moll, J, Burris, HA (2009) A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 15: pp. 6694-6701 CrossRef
31. Traynor, AM, Hewitt, M, Liu, G, Flaherty, KT, Clark, J, Freedman, SJ, Scott, BB, Leighton, AM, Watson, PA, Zhao, B, O'Dwyer, PJ, Wilding, G (2011) Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 67: pp. 305-314 CrossRef
32. Steeghs, N, Eskens, FA, Gelderblom, H, Verweij, J, Nortier, JW, Ouwerkerk, J, Noort, C, Mariani, M, Spinelli, R, Carpinelli, P, Laffranchi, B, Jonge, MJ (2009) Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol 27: pp. 5094-5101 CrossRef
33. Arkenau, HT, Plummer, R, Molife, LR, Olmos, D, Yap, TA, Squires, M, Lewis, S, Lock, V, Yule, M, Lyons, J, Calvert, H, Judson, I (2012) A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol 23: pp. 1307-1313 CrossRef
34. Sch枚ffski, P, Jones, SF, Dumez, H, Infante, JR, Mieghem, E, Fowst, C, Gerletti, P, Xu, H, Jakubczak, JL, English, PA, Pierce, KJ, Burris, HA (2011) Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. Eur J Cancer 47: pp. 2256-2264 CrossRef
35. Schwartz, GK, Carvajal, RD, Midgley, R, Rodig, SJ, Stockman, PK, Ataman, O, Wilson, D, Das, S, Shapiro, GI (2013) Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs 31: pp. 370-380 CrossRef
36. Kantarjian, HM, Martinelli, G, Jabbour, EJ, Quintas-Cardama, A, Ando, K, Bay, JO, Wei, A, Gropper, S, Papayannidis, C, Owen, K, Pike, L, Schmitt, N, Stockman, PK, Giagounidis, A (2013) Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer 119: pp. 2611-2619 CrossRef
37. Komlodi-Pasztor, E, Sackett, DL, Fojo, AT (2012) Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res 18: pp. 51-63 CrossRef
38. Margolis, RL, Lohez, OD, Andreassen, PR (2003) G1 tetraploidy checkpoint and the suppression of tumorigenesis. J Cell Biochem 88: pp. 673-683 CrossRef
39. Keen, N, Taylor, S (2004) Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 4: pp. 927-936 CrossRef
40. Warner, SL, Munoz, RM, Stafford, P, Koller, E, Hurley, LH, Hoff, DD, Han, H (2006) Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells. Mol Cancer Ther 5: pp. 2450-2458 CrossRef
41. Nair, JS, Stanchina, E, Schwartz, GK (2009) The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. Clin Cancer Res 15: pp. 2022-2030 CrossRef
42. Azzariti, A, Bocci, G, Porcelli, L, Fioravanti, A, Sini, P, Simone, GM, Quatrale, AE, Chiarappa, P, Mangia, A, Sebastian, S, Bufalo, D, Tacca, M, Paradiso, A (2011) Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. Br J Cancer 104: pp. 769-780 CrossRef
43. Gautschi, O, Heighway, J, Mack, PC, Purnell, PR, Lara, PN, Gandara, DR (2008) Aurora kinases as anticancer drug targets. Clin Cancer Res 14: pp. 1639-1648 CrossRef
44. Lens, SM, Voest, EE, Medema, RH (2010) Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 10: pp. 825-841 CrossRef
45. Rath, O, Kozielski, F (2012) Kinesins and cancer. Nat Rev Cancer 12: pp. 527-539 CrossRef - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Oncology
Pharmacology and Toxicology - 出版者：Springer Netherlands
- ISSN：1573-0646
文摘